Centers | ||
Weccome Centre for Anti-Infectives Research | EU-OPENSCREEN | Chemical Genomics Facility at Purdue Institute for Drug Discovery |
WCAIR brings together the Drug Discovery Unit (DDU) , the Mode of Action group and the Parasitology research groups. With the daily interactions of these groups, parasitology and drug discovery can work together in synergy. This empowers us to create... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
Partnerships |
Events |
Jobs |
Pfizer's CTI Establishes New Partnership with UCSFPfizer's Center for Therapeutic Innovation has established a new multi-year research and development partnership with University of California, San Francisco (UCSF). Pfizer will provide $85 million in research and milestone payments over five year... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Vanderbilt Enters Into Collaboration With BMS to Develop Drugs to treat Parkinsons DiseaseVanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Bristol-Myers Squibb Company have entered into a broad collaboration agreement to co-develop new drugs to treat Parkinsons Disease. Under the collaboration agreement VCNDD will identify... View all |
No EVENTS for listing |
No Job Posts |


